Advertisement
Advertisement
U.S. markets open in 5 hours 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
0.8741-0.0419 (-4.57%)
At close: 04:00PM EDT
0.9178 +0.04 (+5.00%)
After hours: 06:28PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close0.9160
Open0.9406
Bid0.0000 x 1000
Ask0.0000 x 1300
Day's Range0.8721 - 0.9499
52 Week Range0.8050 - 4.3400
Volume171,484
Avg. Volume467,658
Market Cap103.676M
Beta (5Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)-0.7710
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OCX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OncoCyte Corporation
    Analyst Report: Abbott LaboratoriesAbbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
  • GlobeNewswire

    Oncocyte Reports Second Quarter 2022 Financial Results

    IRVINE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the second quarter 2022, ended June 30, 2022. Second Quarter and Recent Highlights: Recent rightsizing of organization to match new program priorities is expected to reduce headcount carrying costs

  • GlobeNewswire

    Oncocyte to Participate at Upcoming Investor Conferences

    IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that its management team will participate at the following conferences: UBS Genomics 2.0 and MedTech Innovations SummitPresenting on Thursday, August 11, 2022 at 5:00 p.m. Eastern Time in Dana Point, California. The li

  • Simply Wall St.

    The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable

    Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...

Advertisement
Advertisement